ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0947

Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases

Mehret Birru Talabi1, Traci Kazmerski2, Raelynn O'Leary3, Ashley Deal3, Megan Clowse4, Oilvia Stransky5 and Sonya Borrero5, 1University of Pittsburgh, Pittsburgh, PA, 2Children's Hospital of Pittsburgh, Pittsburgh, 3Carnegie Mellon University School of Design, Pittsburgh, 4Duke University, Durham, NC, 5University of Pittsburgh, Pittsburgh

Meeting: ACR Convergence 2022

Keywords: education, patient, pregnancy, prevention, Women's health

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Given the potential for pregnancy-associated mortality and morbidity, the question of whether and/or when to become pregnant is often a profoundly important decision for people with rheumatic diseases (RMDs). However, many people with RMDs struggle to make informed decisions related to pregnancy because they lack access to targeted, relevant, and accurate information. To meet patients’ information needs and augment family planning care in the rheumatology context, our collaborative team of rheumatologists, women’s health experts, and designers developed a web-based, patient-facing decision aid called MyVoice:Rheum.

Methods: We followed best practices for decision aid development as described by the International Patient Decision Aid Standards, and organized the MyVoice:Rheum by Self-Determination Theory domains of patient autonomy (e.g., choice), competence (e.g., knowledge generation), and relatedness (e.g., confidence to communicate with clinicians). Consistent with best practices, we convened a stakeholder panel of reproductive-age women with RMDs to provide feedback throughout about the functionality, design, and content of MyVoice:Rheum prototypes. Content for the tool was abstracted from consensus recommendations about pregnancy, fertility, contraception, and medication safety during pregnancy and lactation from the American College of Rheumatology Guide for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Findings from our prior qualitative studies with patients and rheumatologists also informed content regarding abortion care, parenting, and patient-provider communication. To assess usability, MyVoice:Rheum designers led one-on-one beta-testing sessions with women with RMDs, who were asked to think aloud about their reactions and observations while navigating the tool.

Results: A prototype of the MyVoice:Rheum decision aid was finalized in September 2021.MyVoice:Rheum users are first asked to indicate their RMD diagnosis(-es). Users are next presented with information that is both disease-specific and general. Interactive exercises support reproductive autonomy by allowing users to compare and contrast options for family formation and to freely navigate the tool. A digital notepad is provided to record thoughts and questions to support knowledge generation and competence. When users complete MyVoice:Rheum, a personalized summary sheet is generated that includes facts about the topics that the user perused, and sample questions to prompt family planning conversations with rheumatologists and build communication self-efficacy. Our beta testing results found that users (N=9) either “strongly agreed” or “agreed” on five-item Likert scales that the tool provided salient, trustworthy, and clear information about family planning and RMDs.

Conclusion: The MyVoice:Rheum decision aid is currently undergoing pilot testing to assess its feasibility and acceptability among reproductive-age women with RMDs in the rheumatology clinical setting. A future study will evaluate the impact of MyVoice:Rheum on patient-centered and clinical outcomes in the rheumatology clinical care context.


Disclosures: M. Birru Talabi, None; T. Kazmerski, None; R. O'Leary, None; A. Deal, None; M. Clowse, Exagen; O. Stransky, None; S. Borrero, None.

To cite this abstract in AMA style:

Birru Talabi M, Kazmerski T, O'Leary R, Deal A, Clowse M, Stransky O, Borrero S. Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-of-a-person-centered-family-planning-decision-aid-for-women-with-rheumatic-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-person-centered-family-planning-decision-aid-for-women-with-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology